Contact: Sarah Seagraves
i2E Vice President for Marketing
(405) 813-2403 or email [email protected]
Oklahoma City-based EpimedX, LLC., has been approved for a matching financing round of $200,000 from i2E, Inc., through the Concept Fund. The i2E funding is part of a total target investment round of $600,000.
EpimedX is developing drug therapies to treat blood diseases such as sickle cell disease, beta-thalassemia and malaria.
The Concept Fund is a state-appropriated investment fund that provides concept funding to small businesses in the state of Oklahoma to develop a marketable concept or product. It is managed by i2E through a collaboration with the Oklahoma Center for the Advancement of Science and Technology.
About EpimedX: Founded in 2011 by Drs. Robert Floyd and Robert Broyles, EpimedX is working to develop cures or effective treatments for the world’s major diseases, including sickle cell disease, beta-thalassemia, malaria, diabetes and other inflammatory diseases and conditions.
About i2E, Inc.: Over its 14-year history, i2E’s nationally recognized services have provided business expertise and funding to Oklahoma’s emerging small businesses. With more than $40 million of investment capital under management, i2E is focused on serving companies at all phases of the business life cycle.
